In response to the FDA approval, consider the inclusion of avapritinib as a treatment option for GIST:

- Initial treatment for unresectable or metastatic GIST in patients with PDGFRA D842V mutation (GIST-5 and SARC-F)
- Treatment option following persistent gross residual disease (R2 resection) in patients with PDGFRA D842V mutation (GIST-6)

Submission from Blueprint Medicines Corporation (01/07/20) to the NCCN Soft Tissue Sarcoma Panel to consider listing, in SARC-F, avapritinib as a preferred treatment option for adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) Exon 18 D842V mutation.

Based upon the review and discussion of the data in the noted reference(s) and the recent FDA approval, the panel consensus was to include avapritinib as a treatment option for GIST as follows:

- Initial treatment for unresectable or metastatic GIST with the corresponding footnote, “Indicated for GIST with PDGFRA exon 18 mutation, including PDGFRA D842V mutations.” This is a category 2A recommendation.
- Treatment option following persistent gross residual disease (R2 resection) in patients with PDGFRA D842V mutation. This is a category 2A recommendation.

See Submission for references.

Submission from Blueprint Medicines Corporation (01/09/20) to the NCCN Soft Tissue Sarcoma Panel to consider listing, in SARC-F, avapritinib as a treatment option for patients with a metastatic or unresectable gastrointestinal stromal tumor (GIST) who have been treated with at least 3 prior lines of therapy (4th line).

Based upon the review and discussion of the data in the noted reference(s), the panel consensus supported the inclusion of avapritinib as a treatment option for GIST progressing after imatinib, sunitinib, and regorafenib. This is a category 2A recommendation (SARC-F).

See Submission for references.